Acumen Pharmaceuticals' (Nasdaq: ABOS) shares were down 90% at $0.25 at Monday's open after it revealed that initial top-line data from its Phase II ALTITUDE-AD clinical trial of sabirnetug (ACU193) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results